Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

Pharmaceutical stocks can bring an element of safety to your portfolio. Why is this the case? These companies make drugs ...

The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024.

AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics, which spun out of Pfizer ...

We recently compiled a list of the 10 Best Halal Dividend Stocks To Invest In. In this article, we are going to take a look ...

BMS’ move for Karuna comes a few weeks after AbbVie agreed an $8.7 billion deal to acquire Cerevel Therapeutics, another company developing a schizophrenia drug with a novel mechanism of action.

Emraclidine is under clinical development by Cerevel Therapeutics and currently in Phase I for Dementia Associated With Alzheimer’s Disease. According to GlobalData, Phase I drugs for Dementia ...

AbbVie also spoke about the disappointing data from Phase II studies of emraclidine in schizophrenia – a drug acquired as part of its $9bn acquisition of Cerevel. The company unveiled data in November ...

Riad Sattouf’s saga of his parents’ failed bicultural marriage, with its harsh depiction of life in rural Syria, has become a literary sensation. By Richard Fausset A popular TV host ...